Search

The perception of health risks can influence people's health behaviors. However, in the context of modern consumer society, few people delve into in-depth discussions on health consumption as a form of health protection behavior. Inspired by the Health Belief Model and Protection Motivation Theory, this study interprets health consumption behavior as a new form of health protection behavior. A survey was conducted on a sample of Chinese youth (N = 885) to explore the mechanisms of action between health risk perception and health consumption behavior using structural equation modeling. The study found that: (1) health risk perception has a significant positive impact on the health consumption behavior of young people; (2) negative emotions and information seeking play mediating roles respectively in the mechanism of the impact of health risk perception on health consumption behavior; and (3) in addition to their individual mediating roles, negative emotions and information seeking behavior collectively play a chained mediation role in this process. Implications of these results, both theoretical and practical, are further discussed. [ABSTRACT FROM AUTHOR]

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous sarcoma characterized by the COL1A1‐PDGFB fusion gene. This study utilized single‐cell RNA sequencing to dissect the cellular and molecular landscape of primary DFSP. Distinct DFSP cell clusters, exhibiting fibroblast‐like traits, revealed variations in pathways associated with proliferation, inflammation and metabolism. Differential gene expression analysis during the differentiation from tumour stem cells to DFSP cells unveiled SMOC2, DCN and TGFBR3 as potential regulators of tumour invasion and immune infiltration through VEGF/TGF‐β signalling modulation. Cellular communication analysis highlighted interactions within DFSP cell clusters and with endothelial cells, implicating molecules such as NAMPT, ANGPT2 and PTN in pathogenesis and treatment resistance. These findings offer insights into DFSP intratumour heterogeneity, elucidate molecular mechanisms underlying tumour behaviour, and suggest potential therapeutic targets. [ABSTRACT FROM AUTHOR]

Objective: Narrowband ultraviolet B (NB‐UVB) has been recommended as first‐line therapy for early‐stage mycosis fungoides (MF) in international guidelines. NB‐UVB can be used as monotherapy or part of a multimodality treatment regimen. There is limited evidence on the effectiveness and optimal patients of NB‐UVB in combination with systemic therapies in MF. We aimed to assess the effectiveness of the combination versus NB‐UVB monotherapy in early‐stage MF and if plaque lesion status was related to these effects. Methods: This observational cohort study included 247 early‐stage MF patients who had received NB‐UVB combined with systemic therapies vs. NB‐UVB monotherapy from 2009 to 2021. The primary outcome was partial or complete response. Overall response rate and median time to response were calculated. Hazard ratios (HRs) were estimated using the Cox model. Results: In 139 plaque‐stage patients, the response rate for combination therapy group was higher than that of monotherapy group (79.0% vs. 54.3%, p = 0.006). The adjusted HR for combination therapy compared with NB‐UVB monotherapy was 3.11 (95% CI 1.72–5.63). The combination therapy group also showed shorter time to response (4 vs. 6 months, p = 0.002). In 108 patch‐stage patients, the response rate and time to response in two treatment groups showed no significant difference. There was therefore an observed interaction with patients' plaque lesion status for the effect size of NB‐UVB combination therapy. No serious adverse events were observed. Conclusions: Adding systemic treatments to NB‐UVB did not improve the treatment outcome of patch‐stage patients, but it surpassed NB‐UVB monotherapy for early‐stage patients with plaques. [ABSTRACT FROM AUTHOR]